Received May 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y012508 | — |
no adverse event; HBP reported patient was administered GARDASIL9 during a temperature excursion. Date of administration was 04/22/2025. No additional details reported. No additional AE reported. No PQC reported. ? Names of vaccines involved (including lot/exp); This spontaneous report was received from a non health professional and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 22-Apr-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (lot #Y012508, expiration date: 01-Jan-2027), dose number 1, (anatomical location and administration route were not reported) as prophylaxis. It was reported that this first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) was administered during a temperature excursion of 0°C, in a time frame of 1 hour 0 minutes; and was confirmed that no previous temperature excursions occurred. No additional details and no additional AEs were reported.